Hermetica Superfood Encyclopedia
The Short Answer
Pseudohypericin is a naphthodianthrone compound derived from Hypericum perforatum (St. John's Wort) that exhibits anti-inflammatory, mood-modulating, and stress-regulating properties. Its primary mechanisms involve inhibition of pro-inflammatory mediators, dopamine-β-hydroxylase enzyme activity, and antagonism of corticotropin-releasing factor 1 (CRF1) receptors.
CategoryNamed Bioactive Compounds
GroupCompound
Evidence LevelModerate
Primary Keywordpseudohypericin benefits
Synergy Pairings3
Pseudohypericin — botanical close-up
Health Benefits
Origin & History
Natural habitat
Pseudohypericin is a black-red aromatic polycyclic dione naturally occurring in Hypericum perforatum (St. John's wort), concentrated in leaves, flowers, and reproductive parts, peaking during flowering. It is typically isolated via methanol or ethanol extraction followed by HPLC purification, yielding ≥98% pure powder (C₃₀H₁₆O₉, MW 520.5).
“As a component of Hypericum perforatum, pseudohypericin has been part of European folk medicine since ancient Greek and Roman times, referenced by Hippocrates and Pliny for wound healing and mood disorders. Western herbalism traditionally used St. John's wort teas and tinctures from the 17th-19th centuries for 'nervous disorders' and melancholy.”Traditional Medicine
Scientific Research
No dedicated randomized controlled trials exist for isolated pseudohypericin. Pharmacokinetic data comes from small studies (n=12-18) using St. John's wort extracts, showing Cmax=10.2 ng/mL, t½=17.19 hr, with good tolerability. Despite promising preclinical antiviral/antiretroviral effects, these have not translated to human RCTs.
Preparation & Dosage
Traditional preparation
No clinically studied dosages exist for isolated pseudohypericin. In St. John's wort extracts standardized to 0.3% hypericins (~0.2% pseudohypericin), typical doses are 300-900 mg/day divided, yielding plasma Cmax ~8-10 ng/mL. Research use concentrations: IC50=15 µg/mL for PKC inhibition, 3 µg/mL for dopamine-β-hydroxylase. Consult a healthcare provider before starting any new supplement.
Nutritional Profile
Pseudohypericin is not a nutrient or food but a naturally occurring naphthodianthrone compound (C30H16O9, MW ~520.44 g/mol) found primarily in Hypericum perforatum (St. John's Wort) and related Hypericum species. It is structurally related to hypericin, differing by one additional hydroxyl group. Key details: • Concentration in St. John's Wort aerial parts: approximately 0.03–0.3% dry weight, typically present at roughly 2–4× the concentration of hypericin in the plant material; standardized St. John's Wort extracts (e.g., 0.3% total hypericins) contain pseudohypericin as the major naphthodianthrone constituent. • Bioactive classification: Polycyclic quinone (naphthodianthrone); functions as a photosensitizing pigment with photoactivatable properties (absorption maxima ~548 nm and ~590 nm). • Bioavailability: Oral bioavailability is low and variable; pseudohypericin reaches peak plasma concentrations (Cmax ~2.7–15 ng/mL after ~300 mg standardized extract doses) within approximately 2–3 hours, with a shorter elimination half-life (~16–24 hours) compared to hypericin (~24–48 hours). It is highly protein-bound (>95%) in plasma. Photodegradation can reduce stability if not protected from light. • No macronutrient content (no protein, fat, carbohydrate, or fiber). • No vitamin or mineral content. • Solubility: Poorly water-soluble; moderately soluble in organic solvents (DMSO, methanol, ethanol). Formulation in lipid-based or micellar delivery systems may enhance absorption. • Co-occurring bioactives in source plant: Typically found alongside hypericin, hyperforin, flavonoids (quercetin, rutin, hyperoside), and phenolic acids, which may contribute to synergistic pharmacological effects.
How It Works
Mechanism of Action
Pseudohypericin suppresses LPS-induced prostaglandin E2 (PGE2) and tumor necrosis factor-alpha (TNF-α) production at concentrations as low as 0.03 µM, indicating potent anti-inflammatory activity at the cyclooxygenase and cytokine signaling level. It inhibits dopamine-β-hydroxylase (DBH) with an IC50 of approximately 3 µg/mL, reducing the enzymatic conversion of dopamine to norepinephrine and thereby influencing catecholamine balance. Additionally, pseudohypericin acts as an antagonist at CRF1 receptors, potentially dampening hypothalamic-pituitary-adrenal (HPA) axis overactivation under stress conditions.
Clinical Evidence
The majority of pseudohypericin research consists of in-vitro and preclinical (animal) studies, with very few isolated clinical trials examining this compound specifically rather than whole St. John's Wort extracts. Anti-inflammatory effects demonstrating PGE2 and TNF-α suppression have been quantified in cell-based LPS models at 0.03 µM, but these findings have not been validated in human randomized controlled trials. Dopamine-β-hydroxylase inhibition has been characterized in enzymatic assays with an IC50 of 3 µg/mL, though no human pharmacokinetic or dose-response data currently establish clinically relevant plasma concentrations. Overall, evidence remains preliminary and exploratory; conclusions about efficacy in humans cannot be drawn without dedicated clinical investigation.
Safety & Interactions
Pseudohypericin, as a constituent of St. John's Wort, shares the well-documented drug interaction profile of that plant, including potent induction of cytochrome P450 3A4 (CYP3A4) and P-glycoprotein, which can significantly reduce plasma levels of medications such as cyclosporine, antiretrovirals, oral contraceptives, and warfarin. Photosensitivity reactions are a recognized concern with hypericin-class compounds, and individuals with fair skin should exercise caution with oral supplementation and sun exposure. Pseudohypericin is contraindicated during pregnancy and breastfeeding due to insufficient safety data and theoretical risks related to catecholamine modulation and HPA axis interference. Concurrent use with serotonergic antidepressants, MAO inhibitors, or triptans carries a theoretical risk of serotonin syndrome and should be avoided without medical supervision.
Synergy Stack
Hermetica Formulation Heuristic
Also Known As
Hypericin analogSt. John's wort anthraquinoneHypericum polycyclic dioneBlack hypericinPseudo-hypericinSJW anthraquinone derivative
Frequently Asked Questions
What is pseudohypericin and how does it differ from hypericin?
Pseudohypericin is a naphthodianthrone polycyclic compound co-occurring with hypericin in Hypericum perforatum, differing by the presence of an additional hydroxyl group that alters its polarity and biological activity profile. While both compounds share photosensitizing properties, pseudohypericin demonstrates distinct CRF1 receptor antagonism and dopamine-β-hydroxylase inhibition that have not been equivalently characterized for hypericin. Standardized St. John's Wort extracts typically contain both compounds, often measured together as 'total hypericins.'
Can pseudohypericin help with anxiety or stress?
Pseudohypericin has demonstrated CRF1 (corticotropin-releasing factor 1) receptor antagonism in preclinical models, a mechanism relevant to stress and anxiety regulation because CRF1 mediates HPA axis activation in response to psychological stressors. Additionally, its inhibition of dopamine-β-hydroxylase at an IC50 of 3 µg/mL may reduce norepinephrine synthesis, potentially blunting adrenergic stress responses. However, no human clinical trials have specifically tested isolated pseudohypericin for anxiety outcomes, so current evidence is limited to in-vitro and animal data.
What foods or plants contain pseudohypericin?
Pseudohypericin is found almost exclusively in plants of the genus Hypericum, with Hypericum perforatum (St. John's Wort) being the primary and most commercially relevant source. The compound concentrates in the dark glands of the plant's flowers and leaves, which appear as black dots visible to the naked eye. Other Hypericum species such as H. calycinum and H. olympicum contain pseudohypericin in smaller or variable quantities, but they are rarely used in commercial supplementation.
Does pseudohypericin interact with antidepressants or other medications?
As a St. John's Wort constituent, pseudohypericin is associated with significant CYP3A4 and P-glycoprotein induction, which accelerates the metabolism of numerous drugs including SSRIs, tricyclic antidepressants, warfarin, cyclosporine, and HIV protease inhibitors, potentially reducing their therapeutic plasma concentrations. Combining pseudohypericin-containing supplements with serotonergic drugs (SSRIs, SNRIs, MAOIs, or triptans) raises a theoretical risk of serotonin syndrome characterized by agitation, hyperthermia, and tachycardia. Patients on any prescription medications should consult a healthcare provider before using St. John's Wort or isolated pseudohypericin supplements.
What is the anti-inflammatory mechanism of pseudohypericin?
Pseudohypericin suppresses lipopolysaccharide (LPS)-induced production of prostaglandin E2 (PGE2) and tumor necrosis factor-alpha (TNF-α) at concentrations as low as 0.03 µM in macrophage cell culture models, suggesting interference with both cyclooxygenase-mediated eicosanoid synthesis and NF-κB-dependent cytokine transcription. This dual suppression of prostanoid and cytokine pathways distinguishes it from single-target anti-inflammatory agents. These findings are currently preclinical, and whether orally consumed pseudohypericin reaches sufficient tissue concentrations in humans to replicate these effects remains unestablished.
Is pseudohypericin safe during pregnancy or while breastfeeding?
There is insufficient human safety data on pseudohypericin use during pregnancy or breastfeeding, and animal studies are limited. Given its potential effects on neurotransmitter synthesis and lack of established safety profile, pregnant and nursing women should consult a healthcare provider before use. Current evidence does not support its use in these populations without professional medical guidance.
How strong is the scientific evidence supporting pseudohypericin's health benefits?
Most evidence for pseudohypericin comes from in-vitro and preclinical animal studies, which show promising anti-inflammatory and potential mood-modulating effects, but no human clinical trials have been completed. The dopamine-β-hydroxylase inhibition and CRF1 receptor antagonism are mechanism-based findings that require human validation before health claims can be substantiated. Current research quality is preliminary, and consumers should be aware that supplement effects may not translate from laboratory conditions to real-world use.
Who would benefit most from taking pseudohypericin supplements?
Pseudohypericin may be of interest to individuals seeking natural anti-inflammatory or stress-response support, though clinical evidence in humans is lacking. Those with mild inflammatory conditions or stress-related concerns might consider it, but individuals taking antidepressants, anxiolytics, or medications with narrow therapeutic windows should first consult a healthcare provider. Currently, without human trials, it is difficult to identify which populations would benefit most from supplementation.
Explore the Full Encyclopedia
7,400+ ingredients researched, verified, and formulated for optimal synergy.
Browse IngredientsThese statements have not been evaluated by the Food and Drug Administration. This content is for informational purposes only and is not intended to diagnose, treat, cure, or prevent any disease.
hermetica-encyclopedia-canary-zzqv9k4w pseudohypericin curated by Hermetica Superfoods at ingredients.hermeticasuperfoods.com and licensed CC BY-NC-SA 4.0 (non-commercial share-alike, attribution required)
